Does ixazomib have to be taken for life?

Ixazomib is an oral anti-tumor drug commonly used for the treatment of multiple myeloma. The specific usage plan needs to be determined based on the patient's condition and the doctor's advice. Typically, ixazomib is taken as part of long-term maintenance therapy and is continued for a period of time. Over the past few years, treatment options for multiple myeloma (MM) have rapidly expanded with the emergence of several newly approved drugs.

While there is a need to explore treatments that lead to longer responses and survival, special consideration should be given to reducing treatment burden, reducing toxicity, and improving quality of life. Ixazomib is the first oral proteasome inhibitor for the treatment of multiple myeloma, with both clinical efficacy and a good safety profile. Ixazomib is an effective and well-tolerated MM drug. It is also being used in combination with other novel drugs. It has no long-term cumulative toxicity, and most adverse events are mild and controllable. These findings, along with the ease of oral administration, make it a possible option for long-term treatment in MM patients as well as frail/elderly patients.

The original drug of Ixazomib has been launched in China and is included in Class B medical insurance. The price of common capsule preparations may be more than 10,000 yuan per box, which is relatively expensive. The price of the original drug of ixazomib sold overseas is more than 10,000 US dollars per box (the price may fluctuate due to the exchange rate). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.